Australian biotech market watch 19/03/10
Friday, 19 March, 2010
At the end of a buoyant week for the stock market, the All Ordinaries is flat as of midday today, up a marginal 6.5 points to 4,884.20.
After Cochlear (ASX:COH) announced a change of chairman as Tommie Bergman indicated he was to step down, stocks in the company have seen a bump, up 3.86% since the announcement to $69.30 today.
Two of the other Big Three have remained fairly steady, with CSL (ASX:CSL) hovering around the $36 mark and ResMed loitering around $6.73.
Xenotransplantation specialists, Living Cell Technology (ASX:LCT), saw a steep rise early in the week, but much of the gains have been lost Thursday and today, with it dropping 2c to 21c, although that's still above the sub-20c mark it was trading at last week.
Mesoblast (ASX:MSB) is fairly steady today, up 1c to $2.06, but saw a tidy 5% lift in yesterday's trading.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
